Vizora日本語

CuoripsCuorips Inc.4894東証グロース医薬品FY ending Mar 2026, consolidated, J-GAAP

Cuorips FY ending Mar 2023 results

Cuorips brought in ¥38.3M in revenue.

It lost about ¥1177 for every ¥100 of sales at the operating level.

Revenue changed +175.1% from the prior year.

What changed from last year

FY ending Mar 2022 → FY ending Mar 2023

Revenue
+175.1%¥13.9M → ¥38.3M
Gross profit
+97.2%¥10.7M → ¥21M
Operating income
Loss-¥373.3M → -¥450.4M
Operating cash flow
Loss-¥220.8M → -¥401.6M
Free cash flow
Loss-¥249.5M → -¥412.2M

Where the money goes

FY ending Mar 2022 → FY ending Mar 2023

Where ¥100 of sales goes

For every ¥100 Cuorips sells, how much goes where, and how much is kept.

FY ending Mar 2023
Cost of sales
¥45
SG&A
¥1232
Operating loss
¥1177
Net loss
¥1181

Annual margin trends

Gross margin54.9%
FY ending Mar 2022: 76.6%76.6%FY ending Mar 2023: 54.9%54.9%FY22FY23
Operating margin-1176.7%
FY ending Mar 2022: -2682.8%-2682.8%FY ending Mar 2023: -1176.7%-1176.7%FY22FY23
Net margin-1181.0%
FY ending Mar 2022: -2697.7%-2697.7%FY ending Mar 2023: -1181.0%-1181.0%FY22FY23

Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.

Sources

Show source documents (1)

  • EDINET (FSA Japan)

    有価証券報告書－第7期(2022/04/01－2023/03/31)

    ID S100RAR32023-06-30Open

Extracted from XBRL: 41 / Derived from other figures: 1

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image